Comparison 3. Efavirenz versus nevirapine: subgroup analyses for concurrent TB treatments.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Virological success	9	2369	Risk Ratio (M‐H, Random, 95% CI)	1.04 [0.99, 1.10]
1.1 Concurrent treatment for TB	4	963	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.99, 1.18]
1.2 No treatment for TB	5	1406	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.95, 1.08]
2 Mortality	8	2317	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.59, 1.19]
2.1 Concurrent treatment for TB	4	963	Risk Ratio (M‐H, Random, 95% CI)	0.69 [0.40, 1.19]
2.2 No treatment for TB	4	1354	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.62, 1.64]
3 Progression to AIDS	5	2005	Risk Ratio (M‐H, Random, 95% CI)	1.23 [0.72, 2.11]
3.1 Concurrent treatment for TB	2	712	Risk Ratio (M‐H, Random, 95% CI)	1.09 [0.62, 1.92]
3.2 No treatment for TB	3	1293	Risk Ratio (M‐H, Random, 95% CI)	1.51 [0.44, 5.16]
4 Discontinuation rate	9	2384	Risk Ratio (M‐H, Random, 95% CI)	0.93 [0.69, 1.25]
4.1 Concurrent treatment for TB	4	963	Risk Ratio (M‐H, Random, 95% CI)	0.92 [0.59, 1.42]
4.2 No treatment for TB	5	1421	Risk Ratio (M‐H, Random, 95% CI)	0.99 [0.63, 1.55]